Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations
- 31 December 1995
- Vol. 118 (6) , 1031-1035
- https://doi.org/10.1016/s0039-6060(05)80110-2
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Treatment of preclinical medullary thyroid carcinoma in MEN 2A gene carrierThe Lancet, 1994
- Clinical Screening as Compared with DNA Analysis in Families with Multiple Endocrine Neoplasia Type 2ANew England Journal of Medicine, 1994
- Predictive DNA Testing and Prophylactic Thyroidectomy in Patients at Risk for Multiple Endocrine Neoplasia Type 2AAnnals of Surgery, 1994
- Direct, non-radioactive detection of mutations in Multiple Endocrine Neoplasia Type 2A familiesHuman Molecular Genetics, 1994
- Identification of the Cys634->Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosisJournal of Endocrinological Investigation, 1994
- Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTCNature Genetics, 1994
- A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinomaNature, 1994
- Mutations in the RET proto-oncogene are associated with MEN 2A and FMTCHuman Molecular Genetics, 1993
- Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2ANature, 1993
- Multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis: Description of a new familyJournal of Endocrinological Investigation, 1993